Operating Income (Loss) in USD of Raphael Pharmaceutical Inc. from Q3 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Raphael Pharmaceutical Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2020 to Q3 2025.
  • Raphael Pharmaceutical Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$251K, a 21.3% increase year-over-year.
  • Raphael Pharmaceutical Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$1.39M, a 33% decline year-over-year.
  • Raphael Pharmaceutical Inc. annual Operating Income (Loss) for 2024 was -$1.51M, a 13.3% decline from 2023.
  • Raphael Pharmaceutical Inc. annual Operating Income (Loss) for 2023 was -$1.33M, a 59.8% increase from 2022.
  • Raphael Pharmaceutical Inc. annual Operating Income (Loss) for 2022 was -$3.32M, a 104% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

Raphael Pharmaceutical Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$1.39M -$251K +$68K +21.3% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 -$1.45M -$315K -$66K -26.5% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-13
Q1 2025 -$1.39M -$425K +$122K +22.3% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-15
Q4 2024 -$1.51M -$394K -$468K -632% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-31
Q3 2024 -$1.04M -$319K +$410K +56.2% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 -$1.45M -$249K +$170K +40.6% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-13
Q1 2024 -$1.62M -$547K -$289K -112% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-15
Q4 2023 -$1.33M $74K +$1.18M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-31
Q3 2023 -$2.51M -$729K +$697K +48.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$3.21M -$419K +$193K +31.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$3.4M -$258K -$83K -47.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$3.32M -$1.1M -$530K -92.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$2.79M -$1.43M -$1.01M -241% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$1.78M -$612K -$227K -59% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$1.55M -$175K +$77K +30.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$1.63M -$574K Oct 1, 2021 Dec 31, 2021 10-K/A 2023-05-25
Q3 2021 -$418K -$183K -77.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$385K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$252K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q3 2020 -$235K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-16

Raphael Pharmaceutical Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$1.51M -$177K -13.3% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-31
2023 -$1.33M +$1.99M +59.8% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-31
2022 -$3.32M -$1.69M -104% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 -$1.63M -$923K -131% Jan 1, 2021 Dec 31, 2021 10-K/A 2023-05-25
2020 -$706K Jan 1, 2020 Dec 31, 2020 10-K 2022-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.